ALLR (Allarity Therapeutics) Other Stockholders Equity: $0.00 Mil (As of Mar. 2026)


ALLR Allarity Therapeutics Inc ALLR
26 GF Score
Price $1.32
! 2 Warning Signs
View Full Analysis

What is Allarity Therapeutics Other Stockholders Equity?

Allarity Therapeutics ALLR +3.10% 26 Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus rates ALLR with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Allarity Therapeutics's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $0.00 Mil.

Allarity Therapeutics's quarterly Other Stockholders Equity increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) but then declined from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Allarity Therapeutics's annual Other Stockholders Equity increased from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($-0.00 Mil) and increased from Dec. 2024 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil).

Allarity Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Allarity Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allarity Therapeutics Other Stockholders Equity Chart

Allarity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial 0.00 -0.00 -0.00 -0.00 0.00

Allarity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 0.00
ALLR
26GF Score
Allarity Therapeutics Inc ALLR
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allarity Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
Allarity Therapeutics (ALLR) has a Other Stockholders Equity of $0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Allarity Therapeutics and its competitors.
Is Allarity Therapeutics' Other Stockholders Equity too high?
Allarity Therapeutics' current Other Stockholders Equity is $0.00 Mil. Overall, Allarity Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' Other Stockholders Equity compare to NCEL and LPCN?
Allarity Therapeutics' Other Stockholders Equity of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Allarity Therapeutics and its competitors. Allarity Therapeutics's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (ALLR) has a current Other Stockholders Equity of $0.00 Mil. The current Other Stockholders Equity is $0.00 Mil. Allarity Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Allarity Therapeutics (ALLR), the current Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allarity Therapeutics Business Description

Address 123 East Tarpon Avenue, Tarpon Springs, FL, USA, 34689
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
26GF Score

Get the complete analysis for ALLR

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.32
Price